Author: Hangping Yao; Xiangyun Lu; Qiong Chen; Kaijin Xu; Yu Chen; Linfang Cheng; Fumin Liu; Zhigang Wu; Haibo Wu; Changzhong Jin; Min Zheng; Nanping Wu; Chao Jiang; Lanjuan Li
Title: Patient-derived mutations impact pathogenicity of SARS-CoV-2 Document date: 2020_4_19
ID: 3eu9umx5_4
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.14.20060160 doi: medRxiv preprint 5 in the S protein is the most variable genomic part in the betacoronavirus group (Wu et al., 69 2020; , and some sites of S protein might be subjected to positive 70 selection (Lv et al., 2020) . Despite the abundant variability of SARS-CoV-2, one key 71 question remains as to whether these mutations hav.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.14.20060160 doi: medRxiv preprint 5 in the S protein is the most variable genomic part in the betacoronavirus group (Wu et al., 69 2020; , and some sites of S protein might be subjected to positive 70 selection (Lv et al., 2020) . Despite the abundant variability of SARS-CoV-2, one key 71 question remains as to whether these mutations have any real functional impact on the 72 pathogenicity of SARS-CoV-2. This is crucial in our understanding of the viral infectious 73 mechanisms and dictates the strategy of drug and vaccine development in preparation for 74 the next stage of the pandemic. 75 To address this, we characterized 11 SARS-CoV-2 viral isolates from patients author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Search related documents:
Co phrase search for related documents- functional impact and viral isolate: 1
- pandemic stage and vaccine drug: 1, 2, 3
- pandemic stage and vaccine drug development: 1
- vaccine drug and viral isolate: 1
- vaccine drug development and viral isolate: 1
Co phrase search for related documents, hyperlinks ordered by date